The pharmacotherapeutic management of pulmonary tuberculosis: an update of the state-of-the-art

References

• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736–1788.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2020. Accessed 2021 Jan 14. Available from: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf?ua=1.
   Google Scholar
• Kyu HH, Maddison ER, Henry NJ, GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the global burden of disease study 2015. Lancet Infect Dis. 2018;18(3):261–284.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. 2019. Cited 2021 Jan 14. Available from: https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDR_TB2019.pdf
   Google Scholar
• United Nations. Transforming our world: the 2030 agenda for sustainable development. 2015. Cited 2021 Jan 20. Available from: https://sustainabledevelopment.un.org/post2015/transformingourworld/publication
   Google Scholar
• World Health Organization. The end TB strategy. 2015. Cited 2021 Jan 20. Available from: http://www.who.int/tb/post2015_TBstrategy.pdf
   Google Scholar
• Dheda K, Cox H, Esmail A, et al. Recent controversies about MDR and XDR-TB: global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Respirology. 2018;23(1):36–45.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017. Cited 2021 Jan 20: https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/
   Google Scholar
• World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. 2020. Cited 2020 Sept 6. Available from: https://www.who.int/publications/i/item/9789240007048
   Google Scholar
• Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030.
   PubMed Web of Science ®Google Scholar
• Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–1598.
   PubMed Web of Science ®Google Scholar
• Gillespie S, Crook A, McHugh T, et al. Consortium RE. 2014. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–1587.
   PubMed Web of Science ®Google Scholar
• Jindani A, Harrison TS, Nunn AJ, et al. High dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–1608.
   PubMed Web of Science ®Google Scholar
• Dean AS, Zignol M, Cabibbe AM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: a multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008.
   PubMed Web of Science ®Google Scholar
• Nolan CM, Goldberg SV. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Int J Tuberc Lung Dis. 2002;6(11):952–958.
   PubMed Web of Science ®Google Scholar
• Kim YH, Suh GY, Chung MP, et al. Treatment of isoniazid-resistant pulmonary tuberculosis. BMC Infect Dis. 2008;8(1):6.
   PubMedGoogle Scholar
• Gegia M, Winters N, Benedetti A, et al. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(2):223–234.
   PubMed Web of Science ®Google Scholar
• Fregonese F, Ahuja SD, Akkerman OW, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018;6(4):265–275.
   PubMed Web of Science ®Google Scholar
• Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93–e142.
   PubMed Web of Science ®Google Scholar
• Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PloS Med. 2012;9(8):e1001300.
   PubMed Web of Science ®Google Scholar
• Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the global tuberculosis network. Int J Infect Dis. 2020;92:S15–S25.
   Web of Science ®Google Scholar
• Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 Sep 8;392(10150):821–834.
   PubMed Web of Science ®Google Scholar
• Piubello A, Souleymane MB, Hassane-Harouna S, et al. Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements. Respir Med. 2020;161:105844.
   PubMed Web of Science ®Google Scholar
• Moodley R, Godec TR, STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev. 2016;25(139):29–35.
   PubMed Web of Science ®Google Scholar
• Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter Regimen for Rifampin-resistant tuberculosis. N Engl J Med. 2019;380(13):1201–1213.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397–2405.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271–3276.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–732.
   PubMed Web of Science ®Google Scholar
• Guan Y, Liu Y. Meta-analysis on effectiveness and safety of Moxifloxacin in treatment of multidrug resistant tuberculosis in adults. Medicine (Baltimore). 2020;99(25):e20648.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. 2013. Cited 2021 Mar 10. Available from: https://apps.who.int/iris/bitstream/handle/10665/84879/9789241505482_eng.pdf;sequence=1
   Google Scholar
• Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015;60(2):188–194.
   PubMed Web of Science ®Google Scholar
• Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699–706.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Fox T, Manning K, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study. Clin Infect Dis. 2019;68(9):1522–1529.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun F, Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: promising but challenging. Drug Dev Res. 2019;80(1):98–105.
   PubMed Web of Science ®Google Scholar
• Reuter A, Furin J. Bedaquiline use in South Africa reveals a lifesaving policy in action. Lancet Respir Med. 2018;6(9):653–655.
   PubMed Web of Science ®Google Scholar
• Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017;50(5):1701462.
   PubMed Web of Science ®Google Scholar
• Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. New Eng J Med. 2012;367(16):1508–1518.
   PubMed Web of Science ®Google Scholar
• Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45(1):161–170.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430–1442.
   PubMed Web of Science ®Google Scholar
• Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2013;68(2):284–293.
   PubMed Web of Science ®Google Scholar
• Gopal M, Padayatchi N, Metcalfe JZ, et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013;17(8):1001–1007.
   PubMed Web of Science ®Google Scholar
• Court R, Centner CM, Chirehwa M, et al. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;105:688–694.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2018. Cited 2021 Mar 10. Available from: http://www.who.int/tb/publications/global_report/en/
   Google Scholar
• Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151–2160.
   PubMed Web of Science ®Google Scholar
• Von Groote-Bidlingmaier F, Patientia R, Sanchez E, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249–259.
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Mohr E, Laxmeshwar C, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis. 2018;18(5):536–544.
   PubMed Web of Science ®Google Scholar
• Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol. 2009;2(3):215–218.
   PubMedGoogle Scholar
• Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. 2019. Cited 2021 Jan 28. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs
   Google Scholar
• De Jager VR, Dawson R, van Niekerk C, et al. Telacebec (Q203), a new antituberculosis agent. N Engl J Med. 2020;382(13):1280–1281.
   PubMed Web of Science ®Google Scholar
• Pethe K, Bifani P, Jang J, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med. 2013;19(9):1157–1160.
   PubMed Web of Science ®Google Scholar
• Lu P, Asseri AH, Kremer M, et al. The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd. Sci Rep. 2018;8(1):2625.
   PubMed Web of Science ®Google Scholar
• Kang S, Kim RY, Seo MJ, et al. Lead optimization of a novel series of imidazo[1,2-a] pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent. J Med Chem. 2014;57(12):5293–5305.
   PubMed Web of Science ®Google Scholar
• Cho YS, Lim HS, Lee SH, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single-dose oral LCB01-0371, a novel oxazolidinone with broad-spectrum activity, in healthy volunteers. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00451–18.
   PubMed Web of Science ®Google Scholar
• Choi Y, Lee SW, Kim A, et al. Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects. J Antimicrob Chemother. 2018;73(1):183–190.
   PubMed Web of Science ®Google Scholar
• Cho YL, Jang J. Development of delpazolid for the treatment of tuberculosis. Appl Sci. 2020;10(7):2211.
   Google Scholar
• Wallis RS, Jakubiec W, Kumar V, et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother. 2011;55(2):567–574.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Dawson R, Friedrich SO, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PloS One. 2014;9(4):e94462.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Jakubiec W, Mitton-Fry M, et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One. 2012;7(1):e30479.
   PubMed Web of Science ®Google Scholar
• Makarov V, Manina G, Mikusova K, et al. Benzothiazinones kill mycobacterium tuberculosis by blocking arabinan synthesis. Science. 2009;324(5928):801–804.
   PubMed Web of Science ®Google Scholar
• Zhang G, Aldrich CC. Macozinone: revised synthesis and crystal structure of a promising new drug for treating drug-sensitive and drug-resistant tuberculosis. Acta Crystallogr C Struct Chem. 2019;75(Pt 8):1031–1035.
   PubMedGoogle Scholar
• Lupien A, Vocat A, Foo CS, et al. Optimized background regimen for treatment of active tuberculosis with the next-generation Benzothiazinone Macozinone (PBTZ169). Antimicrob Agents Chemother. 2018;62(11):e00840–18.
   PubMed Web of Science ®Google Scholar
• Park M, Satta G, Kon OM. An update on multidrug-resistant tuberculosis. Clin Med (Lond). 2019 Mar;19(2):135–139.
   PubMed Web of Science ®Google Scholar
• Miotto P, Cirillo DM, Migliori GB, et al. Drug resistance in mycobacterium tuberculosis: molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness. Chest. 2015;147(4):1135–1143.
   PubMed Web of Science ®Google Scholar
• Pontali E, Visca D, Centis R, et al. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management. Curr Opin Pulm Med. 2018;24(3):244–252.
   PubMed Web of Science ®Google Scholar
• Lange C, Dheda K, Chesov D, et al. Management of drug-resistant tuberculosis. Lancet. 2019;394(10202):953–966.
   PubMed Web of Science ®Google Scholar
• Günther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med (Lond). 2014;14(3):279–285.
   PubMed Web of Science ®Google Scholar
• Günther G, van Leth F, Alexandru S, et al. Clinical management of multidrug-resistant tuberculosis in 16 European Countries. Am J Respir Crit Care Med. 2018;198(3):379–386.
   PubMed Web of Science ®Google Scholar
• Pontali E, Matteelli A, Migliori GB. Drug-resistant tuberculosis. Curr Opin Pulm Med. 2013;19(3):266–272.
   PubMed Web of Science ®Google Scholar
• Borisov S, Danila E, Maryandyshev A, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019;54(6):1901522.
   PubMed Web of Science ®Google Scholar
• Akkerman O, Aleksa A, Alffenaar JW, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: a global feasibility study. Int J Infect Dis. 2019;83:72–76.
   PubMed Web of Science ®Google Scholar
• Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis. 2008;21(6):587–595.
   PubMed Web of Science ®Google Scholar
• Villellas C, Coeck N, Meehan CJ, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother. 2017 Mar 1;72(3):684–690.
   PubMed Web of Science ®Google Scholar
• Koch A, Cox H, Mizrahi V. Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Curr Opin Pharmacol. 2018 Oct;42:7–15.
   PubMed Web of Science ®Google Scholar
• Keshavjee S, Amanullah F, Cattamanchi A, et al. Moving toward tuberculosis elimination. Critical issues for research in diagnostics and therapeutics for tuberculosis infection. Am J Respir Crit Care Med. 2019;199(5):564–571.
   PubMed Web of Science ®Google Scholar
• Rakesh K, Shantharam C, Sridhara M, et al. Benzisoxazole: a privileged scaffold for medicinal chemistry. MedChemComm. 2017;8(11):2023–2039.
   PubMed Web of Science ®Google Scholar
• Zhao C, Rakesh KP, Ravidar L, et al. Pharmaceutical and medicinal significance of sulfur (SVI)-containing motifs for drug discovery: a critical review. Eur J Med Chem. 2019 Jan 15;162:679–734.
   PubMed Web of Science ®Google Scholar
• Fang W-Y, Ravindar L, Rakesh KP, et al. Synthetic approaches and pharmaceutical applications of chloro-containing molecules for drug discovery: a critical review. Eur J Med Chem. 2019 Jul 1;173:117–153.
   PubMed Web of Science ®Google Scholar
• Verma SK, Verma R, Verma S, et al. Anti-tuberculosis activity and its structure-activity relationship (SAR) studies of oxadiazole derivatives: a key review. Eur J Med Chem. 2021 Jan 1;209:112886.
   PubMed Web of Science ®Google Scholar